Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Adaptive, Biogen in Immuno Services Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Adaptive, Biogen in Immuno Services Pact

To study biomarkers in autoimmune diseases

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Adaptive Biotechnologies has signed an agreement with Biogen Idec for the study of the immune repertoire and immunological biomarkers in hard to treat autoimmune diseases. Adaptive will use its immune profiling assay, immunoSEQ, to characterize the immune repertoire of patient samples with autoimmune disorders with high unmet medical needs. The immunoSEQ assay uses high throughput next-generation sequencing to characterize the repertoire of T and B cell receptors, which can be useful to monitor the immune status of patients with autoimmune diseases and to assess the impact of treatments.
 
“We are delighted to collaborate with Biogen Idec to help further characterize the immune status of patients with autoimmune diseases who are often quite heterogeneous and therefore, difficult to treat without a more personalized approach,” said Chad Robins, chief executive officer and founder of Adaptive Biotechnologies. “Partnering with Biogen Idec fits squarely with Adaptive’s dual commitment to a deeper understanding of complex diseases as well as to finding better means to treat them.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics